We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01519570
Recruitment Status : Completed
First Posted : January 27, 2012
Last Update Posted : January 27, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Despite the significant benefits of herpes zoster vaccine (HZV), vaccination rates remain low. Electronic medical records (EMR) can serve as a practical strategy to better facilitate the application of preventative health care, such as increasing immunization rates. A new care model that can increase the herpes zoster vaccination rate, as well as other preventative health services, is warranted. The objective of this study is to investigate if the functions of an EMR, in combination with a pharmacist as part of the care team, can improve the herpes zoster vaccination rate.

Condition or disease Intervention/treatment
Herpes Zoster Disease Other: An informational packet regarding shingles and the HZV was sent to patients identified by the EMR

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2589 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Use of an Electronic Medical Record to Improve Standard Practice in the Primary Care Setting: A Randomized-Controlled Study of Herpes Zoster Vaccination Rates
Study Start Date : March 2011
Primary Completion Date : December 2011
Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shingles
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: An informational packet regarding shingles and the HZV Other: An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
No Intervention: Standard medical care from their primary care physician


Outcome Measures

Primary Outcome Measures :
  1. Number of participants who received the herpes zoster vaccine [ Time Frame: 6 months ]
    Six months after the intervention, a second EMR report was generated to determine the change in vaccination rate of both the intervention and control groups.


Secondary Outcome Measures :
  1. Difference in vaccination rates between patients who recieved a mailed letter versus a secure email [ Time Frame: 6 months ]
    Difference in vaccination rates between patients sent communications via US postal service (USPS) and those sent communications via electronic patient portal (EPP)

  2. Amount of time required by a clinical pharmacist to manage this workflow [ Time Frame: 6 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Greater than 60 years of age

Exclusion Criteria:

  • Documented herpes zoster vaccine in the EMR
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01519570


Locations
United States, Ohio
The Ohio State University Martha Morehouse General Internal Medicine Clinic
Columbus, Ohio, United States, 43221
Sponsors and Collaborators
Ohio State University
Investigators
Principal Investigator: Stuart J Beatty, PharmD Ohio State University
Study Chair: Shelley H Otsuka, PharmD The Ohio State Univeristy
Study Chair: Neeraj H Tayal, MD Ohio State University
Study Chair: Kyle Porter, MAS Ohio State University
Study Chair: Peter J Embi, MD, MS Ohio State University
More Information

Responsible Party: Stuart Beatty, Assistant Professor, Ohio State University
ClinicalTrials.gov Identifier: NCT01519570     History of Changes
Other Study ID Numbers: 2010H0290
First Posted: January 27, 2012    Key Record Dates
Last Update Posted: January 27, 2012
Last Verified: January 2012

Keywords provided by Stuart Beatty, Ohio State University:
Herpes Zoster vaccine
Electronic patient portal
Electronic medical record
Primary care
Immunizations

Additional relevant MeSH terms:
Herpes Zoster
Herpesviridae Infections
DNA Virus Infections
Virus Diseases